Home » Pipeline
Pipeline
September 2, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| CStone Pharmaceuticals | avapritinib | GIST | Phase 1 trial initiated |
| CStone Pharmaceuticals | CS3002 | advanced solid tumors | Phase 1 trial initiated enrolling subjects in Australia |
| Alkahest | GRF6021 | Primary hip or knee arthroplasty | Phase 2 trial initiated enrolling 45 subjects |
| Mag Force AG | NanoTherm therapy | Cancer lesions for prostate cancer | Phase 2 trial initiated enrolling 120 male subjects at the Texas Urology Group, the University of Texas, San Antonio and the University of Washington, Seattle |
| Aimmune Therapeutics, Inc. | AR201 | egg allergy | Phase 2 trial initiated enrolling 84 children, adolescents and young adults ages 4 to 26 years of age with hen egg allergy at 15 sites in the U.S. |
| Fulcrum Therapeutics | Losmapimod (selective p38alpha/beta MAPK inhibitor) | facioscapulohumeral muscular dystrophy (FSHD) | Phase 2b trial initiated enrolling subjects with genetically confirmed FSHD |
| Mitsubishi Tanabe Pharma Corporation | ND0612 | Parkinson's disease with motor fluctuations | Phase 3 trial initiated enrolling 300 subjects with PD experiencing motor fluctuations, whose symptoms are no longer controlled by conventional treatments at approximately 120 sites globally |
| VenatoRx Pharmaceuticals | cefepime/VNRX-5133 | complicated urinary tract infection (cUTI) | Phase 3 trial initiated enrolling 582 adult subjects with cUTI, including acute pyelonephritis |
| DiscGenics, Inc. | IDCT | degenerative disc disease (DDD) | Fast Track designation granted by the FDA |
| CrystalGenomics, Inc. | CG-745 | pancreatic cancer | Orphan Drug Designation granted by the FDA |
| Kyowa Kirin Co., Ltd. | NOURIANZ (istradefylline) | Parkinson’s disease | Approval granted by the FDA |
| Eli Lilly and Company | Taltz (ixekizumab) injection 80 mg/mL | active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA) | Approval granted by the FDA |
